Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Companyâs lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļCLYM
āļāļ·āđāļāļāļĢāļīāļĐāļąāļClimb Bio Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļAug 10, 2021
āļāļĩāļāļĩāđāļBrennan (Aoife M)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ17
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļAug 10
āļāļĩāđāļāļĒāļđāđ20 William Street
āđāļĄāļ·āļāļWELLESLEY HILLS
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ02481
āđāļāļĢāļĻāļąāļāļāđ18668572596
āđāļ§āđāļāđāļāļāđhttps://climbbio.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļCLYM
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļAug 10, 2021
āļāļĩāļāļĩāđāļBrennan (Aoife M)
Dr. Aoife M. Brennan, M.D.
Dr. Aoife M. Brennan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Mr. Alexander (Bo) Cumbo
Independent Director
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
Dr. Susan Altschuller, Ph.D.
Dr. Susan Altschuller, Ph.D.
Chief Financial Officer, Principal Accounting Officer, Treasurer
Chief Financial Officer, Principal Accounting Officer, Treasurer
Ms. Perrin Wilson, Ph.D.
Chief Business Officer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Aoife M. Brennan, M.D.
Dr. Aoife M. Brennan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Mr. Alexander (Bo) Cumbo
Independent Director